2025-09069Notice

Draft Guide Helps Speed Generic Psoriasis Cream Approvals

Published Date: 5/21/2025

Notice

Summary

The FDA just released a draft guide to help drug makers test roflumilast cream, a medicine for skin problems. This guide shows how to prove new versions work just as well as the original, making it easier and faster to get approval. If you’re in the drug business, keep an eye out—final rules could speed up your product launches and save money!

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

Draft FDA Guidance for Roflumilast

The FDA released a draft guidance titled "Draft Guidance on Roflumilast." When finalized, it will provide product-specific recommendations on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for roflumilast topical cream.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
5/21/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register